X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to co-develop VRG50635, Verge’s potent, orally bioavailable PIKfyve inhibitor, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS), in Europe, Central and South America, Southeast Asia and Japan.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Product Name: VRG50635
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ferrer Internacional
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2024
Details:
VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS. It is under phase 1 clinical development for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Product Name: VRG50635
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
VRG50635 is a PIKfyve Inhibitor, small molecule drug therapy, administered orally, currently being investigated for amyotrophic lateral sclerosis treatment.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Product Name: VRG50635
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Under the collaboration, Verge will use CONVERGE®, its all-in-human, AI-powered platform, to identify novel therapeutic targets by using data generated from postmortem brain tissue provided by schizophrenia patients and healthy donors.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Pritzker Neuropsychiatric Disorders Research Consortium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 31, 2023
Details:
The collaboration aims to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD), by leveraging Stem Pharm's cutting-edge human-first technologies and expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Stem Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 10, 2023
Details:
The collaboration aims to identify novel drug targets for rare neurodegenerative and neuromuscular diseases by leveraging CONVERGE, a full-stack platform that combines highly predictive human tissue datasets with machine learning to find new targets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: $882.0 million Upfront Cash: $42.0 million
Deal Type: Collaboration September 08, 2023
Details:
VRG50635 is a potential best-in-class small molecule inhibitor of PIKfyve for treatment of ALS. PIKfyve is a new therapeutic target for ALS discovered using CONVERGE™, the company’s all-in-human, AI-powered platform.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Product Name: VRG50635
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
VRG50635 is a potent PIKfyve inhibitor that restores endolysosomal function in ALS patient neurons and has shown efficacy in multiple preclinical studies in ALS-relevant models of motor neuron degeneration.
Lead Product(s): VRG50635
Therapeutic Area: Neurology Product Name: VRG50635
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Funding from the Series B will be used to exponentially grow the number of preclinical and clinical programs in Verge’s pipeline and advance its lead programs through clinical testing.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: BlackRock
Deal Size: $98.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 16, 2021
Details:
In an in vivo study of SARS-CoV-2 infected hamsters, following four-day treatment, animals treated with VRG101 at 50 mg/kg showed significant improvement in lung pathology compared to vehicle controls.
Lead Product(s): VRG101
Therapeutic Area: Infections and Infectious Diseases Product Name: VRG101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
